Effect of Interleukin-1 receptor antagonist on insulin sensitivity in obese, insulin resistant individuals

Effect of Interleukin-1 receptor antagonist on insulin sensitivity in obese, insulin resistant individuals - Interleukin-1 receptor antagonist and insulin sensitivity

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON33714

Enrollment

Registered

2009-04-03

Start date

2009-03-03

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

maturity-onset diabetes type 2 diabetes mellitus

Interventions

150 mg of anakinra once daily by a subcutaneous injection during 4 weeks.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: body mass index > 30 kg/m2 3 or more characteristics of the metabolic syndrome

Exclusion criteria

Exclusion criteria: elevated risk for infections pregnancy or breast-feeding liver or renal disease

Design outcomes

Primary

Measure	Time frame
insulin sensitivity after 4 weeks treatment with anakinra compared with placebo.	—

Secondary

Measure	Time frame
pancreatic beta-cell function fat cell morfology Insulin sensitivity of fat cells glucose control (fasting glucose, HbA1c) concentration of hormonal (leptin, adiponectin, insulin, glucagon) and inflammatory factors (Interleukin 1, 6, 18, hsCRP) and lipid profile	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)